CN109071549B - Pde1抑制剂 - Google Patents

Pde1抑制剂 Download PDF

Info

Publication number
CN109071549B
CN109071549B CN201780022870.0A CN201780022870A CN109071549B CN 109071549 B CN109071549 B CN 109071549B CN 201780022870 A CN201780022870 A CN 201780022870A CN 109071549 B CN109071549 B CN 109071549B
Authority
CN
China
Prior art keywords
methyl
pyrazolo
pyridin
compound
tetrahydropyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780022870.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109071549A (zh
Inventor
K·朱尔
M·杰辛
M·朗格路
P·J·V·维塔尔
M·马里戈
J·凯勒
L·K·拉斯穆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN109071549A publication Critical patent/CN109071549A/zh
Application granted granted Critical
Publication of CN109071549B publication Critical patent/CN109071549B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780022870.0A 2016-04-12 2017-04-07 Pde1抑制剂 Expired - Fee Related CN109071549B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600221 2016-04-12
DKPA201600221 2016-04-12
PCT/EP2017/058332 WO2017178350A1 (en) 2016-04-12 2017-04-07 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors

Publications (2)

Publication Number Publication Date
CN109071549A CN109071549A (zh) 2018-12-21
CN109071549B true CN109071549B (zh) 2021-11-30

Family

ID=58489694

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780022870.0A Expired - Fee Related CN109071549B (zh) 2016-04-12 2017-04-07 Pde1抑制剂

Country Status (43)

Country Link
US (3) US20170291901A1 (cg-RX-API-DMAC7.html)
EP (1) EP3442975B1 (cg-RX-API-DMAC7.html)
JP (1) JP7093306B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180133413A (cg-RX-API-DMAC7.html)
CN (1) CN109071549B (cg-RX-API-DMAC7.html)
AR (1) AR108109A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017250431B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017026278A2 (cg-RX-API-DMAC7.html)
CA (1) CA3020053A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018002881A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018010323A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180470A (cg-RX-API-DMAC7.html)
CY (1) CY1123269T1 (cg-RX-API-DMAC7.html)
DK (1) DK3442975T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2018000201A (cg-RX-API-DMAC7.html)
EA (1) EA035197B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP18074641A (cg-RX-API-DMAC7.html)
ES (1) ES2814289T3 (cg-RX-API-DMAC7.html)
GE (2) GEAP201914901A (cg-RX-API-DMAC7.html)
HR (1) HRP20201331T1 (cg-RX-API-DMAC7.html)
HU (1) HUE050320T2 (cg-RX-API-DMAC7.html)
IL (1) IL262257B (cg-RX-API-DMAC7.html)
LT (1) LT3442975T (cg-RX-API-DMAC7.html)
MA (1) MA44656B1 (cg-RX-API-DMAC7.html)
ME (1) ME03820B (cg-RX-API-DMAC7.html)
MX (1) MX374251B (cg-RX-API-DMAC7.html)
MY (1) MY194722A (cg-RX-API-DMAC7.html)
NI (1) NI201800092A (cg-RX-API-DMAC7.html)
PE (1) PE20181853A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018502168A1 (cg-RX-API-DMAC7.html)
PL (1) PL3442975T3 (cg-RX-API-DMAC7.html)
PT (1) PT3442975T (cg-RX-API-DMAC7.html)
RS (1) RS60714B1 (cg-RX-API-DMAC7.html)
RU (1) RU2018133391A (cg-RX-API-DMAC7.html)
SG (1) SG11201808221QA (cg-RX-API-DMAC7.html)
SI (1) SI3442975T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000446T1 (cg-RX-API-DMAC7.html)
SV (1) SV2018005753A (cg-RX-API-DMAC7.html)
TN (1) TN2018000321A1 (cg-RX-API-DMAC7.html)
TW (1) TWI729109B (cg-RX-API-DMAC7.html)
UA (1) UA121925C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017178350A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201806407B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
RU2019108717A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
LT3532064T (lt) 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
EP3562828B1 (en) 2016-12-28 2026-03-18 Dart Neuroscience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
US20220184240A1 (en) 2019-04-12 2022-06-16 Intra-Cellular Therapies, Inc. Organic compounds
CN115304607B (zh) * 2022-07-06 2023-06-27 华南农业大学 吡唑并嘧啶衍生物的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018474A1 (de) * 2002-08-23 2004-03-04 Bayer Healthcare Ag Phenyl-substituierte pyrazolopyrimidine
WO2004026876A1 (de) * 2002-08-23 2004-04-01 Bayer Healthcare Ag Alkyl-substituierte pyrazolopyrimidine
EP2305262A1 (de) * 2002-08-23 2011-04-06 Boehringer Ingelheim International GmbH Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
EP1626971B1 (de) * 2003-05-09 2011-08-10 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
WO2011153136A1 (en) * 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
CN101687876B (zh) * 2007-05-11 2012-12-12 辉瑞有限公司 氨基杂环化合物
WO2015091805A1 (en) * 2013-12-19 2015-06-25 H. Lundbeck A/S Quinazolin-thf-amines as pde1 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) * 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
EP1919287A4 (en) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
EP2227472A1 (en) 2007-11-30 2010-09-15 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
EP3181566A1 (en) 2010-09-20 2017-06-21 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
US20130196986A1 (en) 2010-09-21 2013-08-01 Marc Labroli Triazolopyrazinones as p2x7 receptor antagonists
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
MX381326B (es) 2011-10-10 2025-03-12 H Lundbeck As Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos
EP2807163B1 (en) 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
WO2016042775A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JP2018508555A (ja) 2015-03-16 2018-03-29 大日本住友製薬株式会社 二環性イミダゾロ誘導体
TW201643167A (zh) 2015-04-22 2016-12-16 H 朗德貝克公司 作爲pde1抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JP2018076285A (ja) 2016-09-14 2018-05-17 大日本住友製薬株式会社 二環性イミダゾロ誘導体を含む医薬
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
LT3532064T (lt) 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
RU2019108717A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018474A1 (de) * 2002-08-23 2004-03-04 Bayer Healthcare Ag Phenyl-substituierte pyrazolopyrimidine
WO2004026876A1 (de) * 2002-08-23 2004-04-01 Bayer Healthcare Ag Alkyl-substituierte pyrazolopyrimidine
EP2305262A1 (de) * 2002-08-23 2011-04-06 Boehringer Ingelheim International GmbH Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
EP1626971B1 (de) * 2003-05-09 2011-08-10 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
CN101687876B (zh) * 2007-05-11 2012-12-12 辉瑞有限公司 氨基杂环化合物
WO2011153136A1 (en) * 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2015091805A1 (en) * 2013-12-19 2015-06-25 H. Lundbeck A/S Quinazolin-thf-amines as pde1 inhibitors

Also Published As

Publication number Publication date
ES2814289T3 (es) 2021-03-26
US10538525B2 (en) 2020-01-21
GEP20207057B (en) 2020-01-27
JP2019517996A (ja) 2019-06-27
NI201800092A (es) 2019-03-14
IL262257B (en) 2020-11-30
CY1123269T1 (el) 2021-12-31
KR20180133413A (ko) 2018-12-14
TW201738242A (zh) 2017-11-01
RS60714B1 (sr) 2020-09-30
PT3442975T (pt) 2020-09-03
IL262257A (en) 2018-11-29
HRP20201331T1 (hr) 2020-11-27
DOP2018000201A (es) 2018-11-15
SMT202000446T1 (it) 2020-09-10
HUE050320T2 (hu) 2020-11-30
DK3442975T3 (da) 2020-08-24
MX2018012496A (es) 2019-02-21
LT3442975T (lt) 2020-09-25
CN109071549A (zh) 2018-12-21
ECSP18074641A (es) 2018-10-31
AU2017250431B2 (en) 2020-07-16
AU2017250431A1 (en) 2018-10-11
SV2018005753A (es) 2018-11-27
US20190194204A1 (en) 2019-06-27
CR20180470A (es) 2018-12-21
AR108109A1 (es) 2018-07-18
RU2018133391A (ru) 2020-05-12
EA035197B1 (ru) 2020-05-14
PL3442975T3 (pl) 2020-11-16
EP3442975B1 (en) 2020-07-29
EP3442975A1 (en) 2019-02-20
SI3442975T1 (sl) 2020-10-30
JP7093306B2 (ja) 2022-06-29
CO2018010323A2 (es) 2018-12-14
PE20181853A1 (es) 2018-12-03
MX374251B (es) 2025-03-05
CA3020053A1 (en) 2017-10-19
ME03820B (me) 2021-04-20
EA201891897A1 (ru) 2019-03-29
PH12018502168A1 (en) 2019-08-19
MA44656B1 (fr) 2020-10-28
SG11201808221QA (en) 2018-10-30
US11104680B2 (en) 2021-08-31
TWI729109B (zh) 2021-06-01
ZA201806407B (en) 2019-12-18
UA121925C2 (uk) 2020-08-10
US20200102316A1 (en) 2020-04-02
RU2018133391A3 (cg-RX-API-DMAC7.html) 2020-06-23
WO2017178350A1 (en) 2017-10-19
MY194722A (en) 2022-12-15
TN2018000321A1 (en) 2020-01-16
CL2018002881A1 (es) 2018-12-14
US20170291901A1 (en) 2017-10-12
BR112017026278A2 (pt) 2018-09-11
GEAP201914901A (en) 2019-09-25
MA44656A (fr) 2019-02-20

Similar Documents

Publication Publication Date Title
TWI729109B (zh) 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JP2022133462A (ja) タンパク質キナーゼのモジュレータとしてのジアリール大環状化合物
EP2945623B1 (en) Hedgehog pathway signaling inhibitors and therapeutic applications thereof
CN109843884B (zh) 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮
JP2022541127A (ja) キナーゼ阻害剤としての置換された縮合複素芳香族二環式化合物およびその使用
JP6663930B2 (ja) Pde1阻害剤としてのイミダゾピラジノン
CN102762568A (zh) 作为polo样激酶的抑制剂的蝶啶酮
CN106928219A (zh) 含氮稠杂环化合物、制备方法、中间体、组合物和应用
CN112300165B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
TW201004959A (en) Substituted tricyclic derivatives
CN111072676B (zh) 含氮稠合三环衍生物及其用途
CN111018856B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111072663B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN110922408B (zh) 3H-[1,2,3]三唑并[4,5-d]嘧啶-5-胺衍生物及其用途
HK40001748B (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
HK40001748A (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
CN116472042A (zh) 作为gaba a型受体调节剂的2-氧代-二氢喹啉-3-甲酰胺衍生物
HK1088893B (en) SUBSTITUTED 8-PERFLUOROALKYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
HK1088893A1 (en) SUBSTITUTED 8-PERFLUOROALKYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
HK1086012A1 (en) 8-substituted-6, 7, 8, 9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
HK1086012B (en) 8-substituted-6, 7, 8, 9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20211130

CF01 Termination of patent right due to non-payment of annual fee